Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Authors
Keywords
Immune checkpoint blockade, Immuno-oncology, Combination therapy, Epacadostat, Indoximod, BMS-986205
Journal
Current Oncology Reports
Volume 21, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-18
DOI
10.1007/s11912-019-0750-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IDO1 in cancer: a Gemini of immune checkpoints
- (2018) Lijie Zhai et al. Cellular & Molecular Immunology
- 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells
- (2018) Xiuting Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas
- (2018) Anne Mills et al. MODERN PATHOLOGY
- IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
- (2018) Erik A. Dill et al. MODERN PATHOLOGY
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
- (2018) Hatem Soliman et al. Oncotarget
- Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
- (2018) Annabel Meireson et al. Oncotarget
- Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system
- (2018) Soo Jeong Nam et al. OncoImmunology
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
- (2018) Aung Naing et al. CANCER RESEARCH
- Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy
- (2018) Theodore S. Johnson et al. CANCER RESEARCH
- Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
- (2018) Craig L. Slingluff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
- (2018) Nathan Bahary et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.
- (2018) Oliver Dorigo et al. JOURNAL OF CLINICAL ONCOLOGY
- Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
- (2018) Adil Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).
- (2018) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
- (2017) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- In situ click chemistry generation of cyclooxygenase-2 inhibitors
- (2017) Atul Bhardwaj et al. Nature Communications
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
- (2017) Daniel E. Carvajal-Hausdorf et al. Journal for ImmunoTherapy of Cancer
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Next generation predictive biomarkers for immune checkpoint inhibition
- (2016) Yulian Khagi et al. CANCER AND METASTASIS REVIEWS
- STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
- (2016) Henrique Lemos et al. CANCER RESEARCH
- Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
- (2016) A. M. Monjazeb et al. CLINICAL CANCER RESEARCH
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- (2016) Kurt A. Schalper et al. CLINICAL CANCER RESEARCH
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- ACTR-53. INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
- (2016) Yousef Zakharia et al. NEURO-ONCOLOGY
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth
- (2016) Yanling Liu et al. Oncotarget
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of immune checkpoint molecules in endometrial carcinoma
- (2015) JIA LIU et al. Experimental and Therapeutic Medicine
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer
- (2015) Mads Duus Hjortsø et al. OncoImmunology
- Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
- (2015) Debbie M Ferns et al. OncoImmunology
- Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
- (2015) Valentina Folgiero et al. Oncotarget
- Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
- (2014) S Han et al. BRITISH JOURNAL OF CANCER
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
- (2014) Jin Won Kim et al. Gastric Cancer
- Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
- (2014) Sonia Moretti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
- (2014) Minghui Li et al. Journal for ImmunoTherapy of Cancer
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
- (2013) Ameet I. Thaker et al. GASTROENTEROLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
- (2013) Ben C. Creelan et al. OncoImmunology
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer
- (2010) Katsuhiko Shimizu et al. Journal of Thoracic Oncology
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
- (2009) Greg M. Delgoffe et al. IMMUNITY
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
- (2008) Francisco J. Quintana et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now